A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE008 (KOR) · Dr. Kim
consented 2023-04-18
Adverse events
Grade 1 Rash — outcome: RECOVERED/RESOLVED; onset 2023-08-09 (study day 97); relationship: not assessed
Grade 2 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2023-09-10 (study day 129); relationship: N
Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-11-03 (study day 183); relationship: N
Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-11-28 (study day 208); relationship: not assessed
Grade 2 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2024-01-08 (study day 249); relationship: Y
Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2024-03-18 (study day 319); relationship: not assessed
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2024-06-12 (study day 405); relationship: not assessed
Grade 2 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2024-07-20 (study day 443); relationship: N
Grade 2 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2024-07-21 (study day 444); relationship: not assessed
Grade 3 Vomiting — outcome: RECOVERED/RESOLVED; onset 2024-08-24 (study day 478); relationship: not assessed
Data queries
No data queries.